These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 2870611)

  • 1. Xamoterol, a new selective beta-1-adrenoceptor partial agonist, in the treatment of postural hypotension.
    Mehlsen J; Trap-Jensen J
    Acta Med Scand; 1986; 219(2):173-7. PubMed ID: 2870611
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Haemodynamics in postural hypotension--effects of the beta-adrenoceptor partial agonist xamoterol, and pindolol.
    Mehlsen J; Trap-Jensen J
    Eur Heart J; 1990 Apr; 11 Suppl A():56-8. PubMed ID: 1971593
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Differential effects of beta-adrenoceptor partial agonists in patients with postural hypotension.
    Mehlsen J; Stadeager C; Trap-Jensen J
    Eur J Clin Pharmacol; 1993; 44(1):7-11. PubMed ID: 8436159
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A double-blind crossover study of oral xamoterol in postural hypotension due to diabetic autonomic neuropathy.
    Leslie PJ; Thompson C; Clarke BF; Ewing DJ
    Clin Auton Res; 1991 Jun; 1(2):119-23. PubMed ID: 1688039
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of idiopathic orthostatic hypotension with xamoterol.
    Yamashita H; Yahara O; Hasebe N; Kawamura Y; Obara A; Honda H; Kimura T; Onodera S
    Lancet; 1987 Jun; 1(8547):1431-2. PubMed ID: 2884518
    [No Abstract]   [Full Text] [Related]  

  • 6. Xamoterol in the treatment of orthostatic hypotension associated with multiple system atrophy (Shy-Drager syndrome).
    West JN; Stallard TJ; Dimmitt SB; Smith SA; Williams A; Littler WA
    Q J Med; 1990 Feb; 74(274):209-13. PubMed ID: 1971724
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Selective beta-adrenoceptor partial agonist effects of pindolol and xamoterol on skeletal muscle assessed by plasma creatine kinase changes in healthy subjects.
    Tomlinson B; Cruickshank JM; Hayes Y; Renondin JC; Lui JB; Graham BR; Jones A; Lewis AD; Prichard BN
    Br J Clin Pharmacol; 1990 Nov; 30(5):665-72. PubMed ID: 1980200
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lack of tolerance development after long-term administration of the partial beta-adrenoceptor agonist xamoterol.
    Erlemeier HH; Kupper W; Bleifeld W
    Cardiology; 1990; 77(1):30-9. PubMed ID: 1972349
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of xamoterol a new beta-adrenoceptor partial agonist, in patients with angina pectoris.
    Barrios L; Geboers J; Piessens JH; de Geest H
    Eur J Clin Pharmacol; 1986; 29(6):667-71. PubMed ID: 2872055
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative analysis of beta-1 adrenoceptor agonist and antagonist potency and selectivity of cicloprolol, xamoterol and pindolol.
    Hicks PE; Cavero I; Manoury P; Lefevre-Borg F; Langer SZ
    J Pharmacol Exp Ther; 1987 Sep; 242(3):1025-34. PubMed ID: 2888869
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of xamoterol in Shy-Drager syndrome.
    Obara A; Yamashita H; Onodera S; Yahara O; Honda H; Hasebe N
    Circulation; 1992 Feb; 85(2):606-11. PubMed ID: 1346511
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Acute and chronic hemodynamic effects of xamoterol in mild to moderate congestive heart failure.
    Virk SJ; Qiang FX; Anfilogoff NH; Murray RG; Littler WA; Davies MK
    Am J Cardiol; 1991 May; 67(12):48C-52C; discussion 52C-54C. PubMed ID: 1673587
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hemodynamic effects of the beta 1-adrenoceptor partial agonist xamoterol in relation to plasma norepinephrine levels during exercise in patients with left ventricular dysfunction.
    Sato H; Inoue M; Matsuyama T; Ozaki H; Shimazu T; Takeda H; Ishida Y; Kamada T
    Circulation; 1987 Jan; 75(1):213-20. PubMed ID: 2878742
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A comparative study on the ventilatory and haemodynamic effects of xamoterol and atenolol in asthmatic patients.
    Lammers JW; Müller ME; Folgering HT; van Herwaarden CL
    Br J Clin Pharmacol; 1986 Nov; 22(5):595-602. PubMed ID: 2878680
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sympathetic modulation in practice: the German clinical experience.
    Kupper W; Erlemeier HH; Bleifeld W
    Eur Heart J; 1990 Apr; 11 Suppl A():19-25. PubMed ID: 1971586
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Contrasting effects of single doses of pindolol and xamoterol on left ventricular diastolic function.
    Rousseau MF; Pouleur H; Debaisieux JC; Van Eyll C; Charlier AA
    Br J Clin Pharmacol; 1989; 28 Suppl 1(Suppl 1):84S-85S. PubMed ID: 2572264
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Role of adrenergic beta receptor partial agonists in left ventricular failure of ischemic origin. Value of xamoterol (ICI 118,587, Corwin)].
    Rousseau MF; Cheron P; Nannan M; Vincent MF; Lavenne F; Pouleur H
    Ann Med Interne (Paris); 1985; 136(3):247-50. PubMed ID: 2862823
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Xamoterol in patients with dilated cardiomyopathy: an increase in beta-receptors in lymphocytes.
    Watanabe K; Hirokawa Y; Shibata A
    J Cardiol; 1988 Dec; 18(4):1015-25. PubMed ID: 2908309
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Selective beta-1-adrenoceptor partial agonist treatment for congestive heart failure.
    Shabetai R
    Cardiology; 1990; 77(5):357-66. PubMed ID: 1981492
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical efficacy of xamoterol, a beta 1-adrenoceptor partial agonist, in mild to moderate heart failure. U.K. Xamoterol Study Group.
    Waller DG; Webster J; Sykes CA; Bhalla KK; Wray R
    Eur Heart J; 1989 Nov; 10(11):1003-10. PubMed ID: 2574108
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.